

# SAFETY DATA SHEET

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

SPECTROZYME® FXa

of the mixture

Registration number

Synonyms None.

 Product code
 222, 832, 846, 848

 Issue date
 01-December-2017

Version number 02

Revision date 11-July-2017 Supersedes date 14-July-2015

1.2. Relevant identified uses of the substance or mixture and uses advised against

**Identified uses** Research use only.

**Uses advised against**Use in accordance with supplier's recommendations.

1.3. Details of the supplier of the safety data sheet

Corporate Headquarters BioMedica Diagnostics Inc.

94 Wentworth Road, PO Box 1030

Windsor, Nova Scotia CANADA B0N 2T0

Contact person Corporate Phone: 1-902-798-5105

Corporate Fax: 1-902-798-1025 Email: info@biomedicadiagnostics.com Website: www.biomedicadiagnostics.com

1.4. Emergency telephone

number

US, Canada, Puerto Rico & Virgin Islands 1-800-255-3924

International +1-813-248-0585 Australia 1-300-954-583

Brazil 0-800-591-6042 China 400-120-0751 India 000-800-100-4086 Mexico 01-800-099-0731

Contract number MIS9591327

#### **SECTION 2: Hazards identification**

## 2.1. Classification of the substance or mixture

The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies.

## Classification according to Regulation (EC) No 1272/2008 as amended

**Health hazards** 

exposure

Skin corrosion/irritation Category 2 H315 - Causes skin irritation.
Serious eye damage/eye irritation Category 2 H319 - Causes serious eye

irritation.

Specific target organ toxicity - single

Category 3 respiratory tract irritation

H335 - May cause respiratory

irritation.

**Hazard summary** Irritating to eyes, respiratory system and skin.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

**Contains:** N-Methoxycarbonyl-D-cyclohexylglycyl-glycyl-arginine-para-nitroanilide acetate

Hazard pictograms



Signal word Warning

SPECTROZYME® FXa SDS UK

926239 Version #: 02 Revision date: 11-July-2017 Issue date: 01-December-2017

**Hazard statements** 

H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.

**Precautionary statements** 

Prevention

P261 Avoid breathing dust.

P264 Wash thoroughly after handling.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves. P280 Wear eye/face protection.

Response

P302 + P352 IF ON SKIN: Wash with plenty of water.

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present

and easy to do. Continue rinsing.

P312 Call a PÓISON CENTER/doctor if you feel unwell.
P332 + P313 If skin irritation occurs: Get medical advice/attention.
P337 + P313 If eye irritation persists: Get medical advice/attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage

P403 + P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

Disposal

P501 Dispose of contents/container in accordance with local/regional/national/international regulations.

Supplemental label information None.

**2.3. Other hazards**Not a PBT or vPvB substance or mixture.

## **SECTION 3: Composition/information on ingredients**

#### 3.2. Mixtures

**General information** 

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
Glycine	50 - 70	56-40-6 200-272-2	-	-	
Classification: -					
N-Methoxycarbonyl-D-cyclohexylglycy l-glycyl-arginine-para-nitroanilide acetate	30 - 40	None -	-	-	

Classification: Skin Irrit. 2;H315, Eye Irrit. 2;H319, STOT SE 3;H335

Composition comments All concentrations are in percent by weight unless ingredient is a gas. Gas concentrations are in

percent by volume. The full text for all H-statements is displayed in section 16.

**SECTION 4: First aid measures** 

General information Ensure that medical personnel are aware of the material(s) involved, and take precautions to

protect themselves. If you feel unwell, seek medical advice (show the label where possible).

4.1. Description of first aid measures

Inhalation Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON

CENTRE or doctor/physician if you feel unwell.

**Skin contact** Remove contaminated clothing. Wash with plenty of soap and water. If skin irritation occurs: Get

medical advice/attention. Wash contaminated clothing before reuse.

Eye contact Do not rub eyes. Immediately flush eyes with plenty of water for at least 15 minutes. Remove

contact lenses, if present and easy to do. Continue rinsing. Get medical attention if irritation

develops and persists.

**Ingestion** Rinse mouth. Get medical attention if symptoms occur.

4.2. Most important symptoms and effects, both acute and

delayed

May cause redness and pain. Symptoms of overexposure may be headache, dizziness, tiredness,

nausea and vomiting.

SPECTROZYME® FXa SDS UK

926239 Version #: 02 Revision date: 11-July-2017 Issue date: 01-December-2017

4.3. Indication of any immediate medical attention and special treatment needed Provide general supportive measures and treat symptomatically.

## **SECTION 5: Firefighting measures**

General fire hazards No unusual fire or explosion hazards noted. Will burn if involved in a fire.

5.1. Extinguishing media

Suitable extinguishing

media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing

media

Do not use water jet as an extinguisher, as this will spread the fire.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

procedures

Use standard firefighting procedures and consider the hazards of other involved materials.

#### **SECTION 6: Accidental release measures**

#### 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency

personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate protective equipment and clothing during clean-up. Avoid inhalation of dust. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in section 8 of the

SDS.

6.2. Environmental precautions

6.3. Methods and material for containment and cleaning up Avoid discharge into drains, water courses or onto the ground. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Collect dust using a vacuum cleaner equipped with HEPA filter. Stop the flow of material, if this is without risk.

Large Spills: Wet down with water and dike for later disposal. Shovel the material into waste

container. Following product recovery, flush area with water.

Small Spills: Sweep up or vacuum up spillage and collect in suitable container for disposal. Clean

surface thoroughly to remove residual contamination.

6.4. Reference to other

sections

For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

#### **SECTION 7: Handling and storage**

7.1. Precautions for safe

handling

Minimise dust generation and accumulation. Provide appropriate exhaust ventilation at places where dust is formed. Avoid breathing dust. Avoid contact with eyes, skin, and clothing. Avoid prolonged exposure. Wear appropriate personal protective equipment. Observe good industrial hygiene practices.

7.2. Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store in a well-ventilated place. Store away from incompatible materials (see section 10 of the SDS).

7.3. Specific end use(s)

Research use only.

#### **SECTION 8: Exposure controls/personal protection**

8.1. Control parameters

Occupational exposure limits

No exposure limits noted for ingredient(s).

No biological exposure limits noted for the ingredient(s).

**Biological limit values** 

Follow standard monitoring procedures.

Recommended monitoring

procedures

Derived no-effect level (DNEL)

Predicted no effect concentrations (PNECs) Not available.

Not available.

8.2. Exposure controls

SDS UK SPECTROZYME® FXa

926239 Version #: 02 Revision date: 11-July-2017 Issue date: 01-December-2017

# Appropriate engineering controls

Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. If engineering measures are not sufficient to maintain concentrations of dust particulates below the OEL (occupational exposure limit), suitable respiratory protection must be worn. If material is ground, cut, or used in any operation which may generate dusts, use appropriate local exhaust ventilation to keep exposures below the recommended exposure limits. Eye wash facilities and emergency shower must be available when handling this product.

#### Individual protection measures, such as personal protective equipment

**General information**Use personal protective equipment as required. Personal protection equipment should be chosen

according to the CEN standards and in discussion with the supplier of the personal protective

equipment.

Eye/face protection

Wear safety goggles and a face shield.

Skin protection

- Hand protection Wear appropriate chemical resistant gloves. Suitable gloves can be recommended by the glove

supplier.

Other Wear appropriate chemical resistant clothing.

Respiratory protection In case of inadequate ventilation or risk of inhalation of dust or fumes, use suitable respiratory

equipment.

**Thermal hazards** Wear appropriate thermal protective clothing, when necessary.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

**Environmental exposure** 

controls

Environmental manager must be informed of all major releases.

## **SECTION 9: Physical and chemical properties**

#### 9.1. Information on basic physical and chemical properties

**Appearance** 

Physical state Solid.

Form White powder.

Colour White.

Odour Not available.
Odour threshold Not available.
pH Not available.
Melting point/freezing point Not available.
Initial boiling point and boiling Not available.

range

Flash point

Evaporation rate

Flammability (solid, gas)

Not available.

Not available.

Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Vapour pressureNot available.Vapour densityNot available.Relative densityNot available.Solubility(ies)Soluble in water.Partition coefficientNot available.

(n-octanol/water)

Auto-ignition temperatureNot available.Decomposition temperatureNot available.ViscosityNot available.Explosive propertiesNot available.Oxidizing propertiesNot available.

**9.2. Other information** No relevant additional information available.

SPECTROZYME® FXa SDS UK

## **SECTION 10: Stability and reactivity**

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions. 10.3. Possibility of hazardous Hazardous polymerisation does not occur.

reactions

Contact with incompatible materials. Strong oxidising agents. Strong acids.

10.6. Hazardous decomposition products

10.4. Conditions to avoid 10.5. Incompatible materials

Carbon monoxide. Carbon dioxide.

# **SECTION 11: Toxicological information**

Occupational exposure to the substance or mixture may cause adverse effects. **General information** 

Information on likely routes of exposure

Inhalation Dust may irritate respiratory system. Prolonged inhalation may be harmful.

Causes skin irritation. Skin contact

Eye contact Causes serious eye irritation. Ingestion May cause discomfort if swallowed.

Symptoms of overexposure may be headache, dizziness, tiredness, nausea and vomiting. May Symptoms

cause redness and pain.

#### 11.1. Information on toxicological effects

May cause discomfort if swallowed. Acute toxicity

Causes skin irritation. Skin corrosion/irritation

Serious eye damage/eye

irritation

Causes serious eye irritation.

Respiratory sensitisation Not a respiratory sensitiser.

Skin sensitisation Not a skin sensitiser.

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Carcinogenicity Not classifiable as to carcinogenicity to humans.

This product is not expected to cause reproductive or developmental effects. Reproductive toxicity

Specific target organ toxicity -

single exposure

May cause respiratory irritation.

Specific target organ toxicity -

repeated exposure

Not classified.

**Aspiration hazard** Not classified. Mixture versus substance

information

Not available.

No other specific acute or chronic health impact noted. Other information

## **SECTION 12: Ecological information**

12.1. Toxicity The product is not classified as environmentally hazardous. However, this does not exclude the

possibility that large or frequent spills can have a harmful or damaging effect on the environment.

12.2. Persistence and

degradability

No data is available on the degradability of this product.

12.3. Bioaccumulative potential

**Partition coefficient** 

n-octanol/water (log Kow)

Not available.

**Bioconcentration factor (BCF)** Not available No data available. 12.4. Mobility in soil

12.5. Results of PBT

and vPvB assessment Not a PBT or vPvB substance or mixture

12.6. Other adverse effects No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

## **SECTION 13: Disposal considerations**

## 13.1. Waste treatment methods

SDS UK SPECTROZYME® FXa

926239 Version #: 02 Revision date: 11-July-2017 Issue date: 01-December-2017 **Residual waste** Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

**Contaminated packaging** Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

**EU waste code**The Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Not applicable.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Dispose of

contents/container in accordance with local/regional/national/international regulations.

#### **SECTION 14: Transport information**

#### ADR

Not regulated as dangerous goods.

**RID** 

Not regulated as dangerous goods.

**ADN** 

Not regulated as dangerous goods.

**IATA** 

Not regulated as dangerous goods.

**IMDG** 

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC

Code

## **SECTION 15: Regulatory information**

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### **EU** regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I and II, as amended

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry, as amended

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA Not listed.

#### **Authorisations**

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended Not listed.

## Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work, as amended

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding, as amended

Not listed.

# Other EU regulations

Directive 2012/18/EU on major accident hazards involving dangerous substances

Not listed.

SPECTROZYME® FXa SDS UK

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with Regulation (EC) 1272/2008 (CLP

Regulation) as amended and respective national laws implementing EC directives. This Safety

Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

In the European Union this product is regulated under the In Vitro Diagnostic Medical Devices

Directive (98/79/EC).

National regulations 15.2. Chemical safety

assessment

Follow national regulation for work with chemical agents. No Chemical Safety Assessment has been carried out.

## **SECTION 16: Other information**

List of abbreviations

DNEL: Derived No-Effect Level.

PNEC: Predicted No-Effect Concentration.

References IARC Monographs. Overall Evaluation of Carcinogenicity

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any H-statements not written out in full under Sections 2 to 15

H315 Causes skin irritation.

H319 Causes serious eye irritation. H335 May cause respiratory irritation.

**Training information** 

Disclaimer

Follow training instructions when handling this material.

The information above is provided in good faith. It is believed to be accurate and represents the best information currently available to us. HOWEVER, WE MAKE NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER TYPE, EXPRESSED OR IMPLIED, WITH RESPECT TO PRODUCTS DESCRIBED OR DATA OR INFORMATION PROVIDED, AND WE ASSUME NO LIABILITY RESULTING FROM THE USE OF SUCH PRODUCTS, DATA OR INFORMATION. Users should make their own investigations to determine the suitability of the information for their particular purposes, and the user assumes all risk arising from their use of the material. The user is required to comply with all laws and regulations relating to the purchase, use, storage and disposal of the material, and must be familiar with and follow generally accepted safe handling procedures. In no event shall BioMedica Diagnostics be liable for any claims, losses, or damages of any individual or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if BioMedica Diagnostics has been advised of the possibility of such damages.

SPECTROZYME® FXa SDS UK

926239 Version #: 02 Revision date: 11-July-2017 Issue date: 01-December-2017